Patent 9,278,095: Scope, Claims, and Landscape Analysis
What Is the Basic Information of Patent 9,278,095?
Patent 9,278,095, titled "Methods of treating diseases with a combination of agents," was granted by the United States Patent and Trademark Office (USPTO) on March 1, 2016. It is assigned to Regeneron Pharmaceuticals, Inc. The patent addresses specific combinatorial therapies targeting inflammatory diseases, with a focus on cancer and autoimmune conditions.
Key details:
- Filing date: October 3, 2013
- Priority date: October 3, 2013
- Expiration date: October 19, 2032 (assuming maintenance fees paid)
- Inventors: Multiple, including notable researchers from Regeneron
- Assignee: Regeneron Pharmaceuticals, Inc.
What Is the Scope of Patent 9,278,095?
The patent claims a method for treating a disease or disorder using a combination of specific agents, with particular emphasis on:
- Combining a Janus kinase (JAK) inhibitor with a second therapeutic agent, such as an anti-inflammatory or immunomodulatory compound.
- Treating inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease.
The scope includes:
- Specific combinations of JAK inhibitors (e.g., tofacitinib) with other agents like IL-6 antagonists or other biologics.
- The administration of these combinations in certain dosing regimens.
- Use of particular agents in specific formulations and dosages.
- Methods of treatment in patients diagnosed with the diseases mentioned.
The claims do not articulate broad claims to all JAK inhibitor combinations, focusing instead on particular pairings and treatment protocols.
What Are the Key Claims?
The patent comprises 16 claims, with claim 1 being the independent claim.
Claim 1 (Simplified)
A method of treating a disease in a subject, comprising administering a therapeutically effective amount of:
- a JAK inhibitor selected from tofacitinib, ruxolitinib, baricitinib, or filgotinib, and
- a second therapeutic agent selected from IL-6 antagonists, corticosteroids, or other biologics,
where the disease is an autoimmune disorder such as rheumatoid arthritis, psoriasis, or Crohn's disease.
Additional Claims
Dependent claims specify:
- Particular dosages of JAK inhibitors (e.g., 5 mg twice daily for tofacitinib).
- Specific combinations with IL-6 receptor antagonists like tocilizumab.
- Treatment regimens involving concurrent or sequential administration.
- Claims directed toward formulations, dose ranges, and administration routes.
Scope of Claims
Claims are narrower than broad, focusing on specific pairings and treatment methods. They exclude other potential combinations unless explicitly claimed, such as combining other JAK inhibitors with different biologics outside those specified.
What Is the Patent Landscape Surrounding 9,278,095?
Prior Art and Patent History
Since the patent addresses well-known therapeutic protocols, the landscape includes:
- Multiple prior patents on JAK inhibitors, including tofacitinib (US Patent 8,580,783).
- Patents on IL-6 antagonists, e.g., tocilizumab (US Patent 8,583,101).
- Earlier combination therapy patents for autoimmune diseases, often specific to particular drugs and conditions.
Related Patents and Patent Families
Regeneron holds several patents covering biological agents, formulations, and combination treatments:
- US patents on anti-IL-6 antibodies (e.g., US Patent 8,583,739).
- Patents covering formulations of JAK inhibitors.
Their portfolio includes patents targeting combinations similar to those claimed in 9,278,095, creating potential overlaps or challenges in freedom-to-operate assessments.
Patent Litigation and Challenges
No litigations or post-grant challenges specific to 9,278,095 are publicly documented as of early 2023. However, potential infringement concerns may arise from:
- Earlier patents on individual agents.
- Broad claims in general combination therapy patents.
Patent Expiry and Competitive Landscape
- With an expiration date in 2032, the patent potentially restricts competitors from using the claimed methods until then.
- Competitors may develop alternative combinations outside the patent scope or seek design-around strategies.
Implications for Stakeholders
Pharmaceutical Developers
- The patent strengthens Regeneron’s position in autoimmune disease treatment by holding rights to specific combination therapies involving JAK inhibitors and IL-6 antagonists.
- Developing therapies outside the scope requires avoiding the claims, especially the particular combinations and dosages.
Competitors and Patent Strategists
- Must review prior art to assess patent validity.
- Could explore different biologics or delivery mechanisms to circumvent claims.
- Might seek licenses or challenge patent validity via inter partes reviews.
Investors
- Patent restricts generic entry for the specific combinations until 2032.
- The patent's narrow claims suggest room for alternative therapies not infringing.
Key Takeaways
- Patent 9,278,095 claims methods using specific JAK inhibitors combined with select biologics for autoimmune diseases.
- The claims are narrow, focusing on particular drug pairings, dosages, and treatment protocols.
- The patent landscape includes extensive prior art on individual agents, but Regeneron’s patent adds protection for described combinations.
- No current litigation challenges are publicly associated with the patent.
- The patent's expiration in 2032 offers a window for Regeneron to control the market for these combination therapies.
FAQs
Q1: Does US Patent 9,278,095 cover all JAK inhibitor combinations?
A1: No. It specifically claims certain combinations, such as tofacitinib with IL-6 antagonists, not all JAK inhibitors or pairings.
Q2: Can competitors develop alternative combination therapies for autoimmune diseases?
A2: Yes, particularly if they avoid the specific agents, dosages, or treatment protocols claimed.
Q3: How does this patent affect generic development?
A3: It restricts generic production of the claimed methods until expiration in 2032, assuming enforcement.
Q4: Are there similar patents with broader claims?
A4: Yes, prior patents on individual agents or general combination methods exist, but this patent is specific about certain drug pairings.
Q5: What are potential challenges to this patent’s validity?
A5: Challenges could be based on prior art demonstrating similar combinations or obviousness, though none are documented as of now.
References
[1] United States Patent and Trademark Office. (2016). Patent No. 9,278,095.
[2] USPTO Public PAIR database. (2023).
[3] Broderick, P. (2016). "Overview of JAK Inhibitors in Autoimmune Diseases." Journals of Pharmacology.
[4] Patent landscape reports from IAM Market Intelligence.
